News
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...
Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
5hon MSN
Shares of Eli Lilly and Co. tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback